Biomarkers and Prognostic Stratification of Squamous Cell Carcinoma of the Oral Cavity in Young Adults: how to personalize therapeutic management?

IF 3.7 3区 医学 Q2 ONCOLOGY Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-09-19 DOI:10.1158/1055-9965.EPI-24-1091
Antoine Dubray-Vautrin, Guillaume Rougier, Christophe Le Tourneau, Wahib Ghanem, Nathalie Badois, Maria Lesnik, Baptiste Sabran, Laurence Bozec, Joey Martin, Olivier Choussy
{"title":"Biomarkers and Prognostic Stratification of Squamous Cell Carcinoma of the Oral Cavity in Young Adults: how to personalize therapeutic management?","authors":"Antoine Dubray-Vautrin, Guillaume Rougier, Christophe Le Tourneau, Wahib Ghanem, Nathalie Badois, Maria Lesnik, Baptiste Sabran, Laurence Bozec, Joey Martin, Olivier Choussy","doi":"10.1158/1055-9965.EPI-24-1091","DOIUrl":null,"url":null,"abstract":"<p><p>Squamous cell carcinomas (SCCs) of the oral cavity in young adults represent a heterogeneous entity. New prognostic biomarkers are described in the literature. The aim was to identify emerging biomarkers and prognostic stratification factors of young population. Clinical, biological, microbiological, histopathological, and molecular markers statistically associated with overall and disease-free survival (OS) and validated in literature. Young adults < 40 years who were non-smokers showed a marginally worse prognosis, while age < 30 years was unfavorable compared to > 30 years. High rate of Neutrophil-to-lymphocyte ratio (NLR) was associated with decreased 5-year disease-specific survival, PDL1 expression correlated with improved OS and recurrence-free survival, presence of Fusobacterium, Mutations in p53, Cyclin D1, and VEGF was associated with reduced OS. Combining these markers in young adult oral cavity SCCs should be used to adapt the intensification of therapy in addition to the TNM classification and minor histo-prognostic factors.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology Biomarkers & Prevention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1055-9965.EPI-24-1091","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Squamous cell carcinomas (SCCs) of the oral cavity in young adults represent a heterogeneous entity. New prognostic biomarkers are described in the literature. The aim was to identify emerging biomarkers and prognostic stratification factors of young population. Clinical, biological, microbiological, histopathological, and molecular markers statistically associated with overall and disease-free survival (OS) and validated in literature. Young adults < 40 years who were non-smokers showed a marginally worse prognosis, while age < 30 years was unfavorable compared to > 30 years. High rate of Neutrophil-to-lymphocyte ratio (NLR) was associated with decreased 5-year disease-specific survival, PDL1 expression correlated with improved OS and recurrence-free survival, presence of Fusobacterium, Mutations in p53, Cyclin D1, and VEGF was associated with reduced OS. Combining these markers in young adult oral cavity SCCs should be used to adapt the intensification of therapy in addition to the TNM classification and minor histo-prognostic factors.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
年轻人口腔鳞状细胞癌的生物标志物和预后分层:如何进行个性化治疗?
青壮年口腔鳞状细胞癌(SCC)是一种异质性肿瘤。文献中描述了新的预后生物标志物。研究的目的是确定新出现的生物标志物和年轻人群的预后分层因素。临床、生物学、微生物学、组织病理学和分子标记与总生存期和无病生存期(OS)相关,并在文献中得到验证。年龄小于40岁且不吸烟的年轻人预后稍差,而年龄小于30岁的年轻人预后比大于30岁的年轻人差。中性粒细胞与淋巴细胞比值(NLR)高与5年疾病特异性生存率降低有关,PDL1表达与OS和无复发生存率改善有关,Fusobacterium、p53、Cyclin D1和VEGF突变与OS降低有关。除了TNM分类和次要组织预后因素外,还应结合这些标记物来调整年轻成人口腔SCC的强化治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Epidemiology Biomarkers & Prevention
Cancer Epidemiology Biomarkers & Prevention 医学-公共卫生、环境卫生与职业卫生
CiteScore
6.50
自引率
2.60%
发文量
538
审稿时长
1.6 months
期刊介绍: Cancer Epidemiology, Biomarkers & Prevention publishes original peer-reviewed, population-based research on cancer etiology, prevention, surveillance, and survivorship. The following topics are of special interest: descriptive, analytical, and molecular epidemiology; biomarkers including assay development, validation, and application; chemoprevention and other types of prevention research in the context of descriptive and observational studies; the role of behavioral factors in cancer etiology and prevention; survivorship studies; risk factors; implementation science and cancer care delivery; and the science of cancer health disparities. Besides welcoming manuscripts that address individual subjects in any of the relevant disciplines, CEBP editors encourage the submission of manuscripts with a transdisciplinary approach.
期刊最新文献
Incidence of serious complications following screening colonoscopy in adults aged 76 to 85 years old. Patterns of subsequent cancer incidence over time in patients with breast cancer. Polygenic risk score, healthy lifestyle score, and colorectal cancer risk: a prospective cohort study. Socioeconomic Inequalities in Participation in Colorectal Cancer Screening in Ontario, Canada: A decomposition analysis. A screen-and-treat strategy for eradication of Helicobacter pylori among patients with family history of gastric cancer in a diverse U.S. population.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1